Bacillus calmette-guerin substrain connaught live antigen
Identification
- Name
- Bacillus calmette-guerin substrain connaught live antigen
- Accession Number
- DB10804
- Type
- Biotech
- Groups
- Approved, Investigational
- Biologic Classification
- Vaccines
Attenuated - Description
Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.
- Synonyms
- BCG, Live, Connaught Strain
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Theracys Injection, powder, lyophilized, for solution 81 mg/3mL Intravesical Sanofi Pasteur Limited 2011-07-22 2017-05-20 US - Categories
- UNII
- 5H5854UBMZ
- CAS number
- Not Available
Pharmacology
- Indication
Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).
- Structured Indications
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Illicit 2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental 5-androstenedione The risk or severity of adverse effects can be increased when 5-androstenedione is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Illicit Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Abciximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abciximab. Approved Abetimus The risk or severity of adverse effects can be increased when Abetimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Abituzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abituzumab. Investigational Acteoside The risk or severity of adverse effects can be increased when Acteoside is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Adecatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Adecatumumab. Investigational Adefovir The risk or severity of adverse effects can be increased when Adefovir is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Aducanumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Aducanumab. Investigational Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Alclometasone The risk or severity of adverse effects can be increased when Alclometasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Investigational Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Withdrawn Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Alicaforsen The risk or severity of adverse effects can be increased when Alicaforsen is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Alirocumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Alirocumab. Approved Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Amatuximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Amatuximab. Investigational Amcinonide The risk or severity of adverse effects can be increased when Amcinonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved AMG 108 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with AMG 108. Investigational Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Androstenedione The risk or severity of adverse effects can be increased when Androstenedione is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Anecortave is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational anecortave acetate The risk or severity of adverse effects can be increased when anecortave acetate is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Anifrolumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Anifrolumab. Investigational Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Apolizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Apolizumab. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ascrinvacumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ascrinvacumab. Investigational Asfotase Alfa The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Asfotase Alfa. Approved, Investigational Atamestane The risk or severity of adverse effects can be increased when Atamestane is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Atezolizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Atezolizumab. Approved, Investigational AVE9633 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with AVE9633. Investigational Avelumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Avelumab. Approved, Investigational Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Bapineuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bapineuzumab. Investigational Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bavituximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bavituximab. Investigational Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bectumomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bectumomab. Investigational Begelomab The risk or severity of adverse effects can be increased when Begelomab is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Investigational Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Belimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Belimumab. Approved Benznidazole The risk or severity of adverse effects can be increased when Benznidazole is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Besilesomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Besilesomab. Approved Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Bevacizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bevacizumab. Approved, Investigational BIIB015 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with BIIB015. Investigational Bimagrumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bimagrumab. Investigational Bivatuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bivatuzumab. Investigational Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Blinatumomab The risk or severity of adverse effects can be increased when Blinatumomab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Blosozumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Blosozumab. Investigational Bococizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bococizumab. Investigational Brentuximab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Brodalumab The risk or severity of adverse effects can be increased when Brodalumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Budesonide The risk or severity of adverse effects can be increased when Budesonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Cabazitaxel The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Canakinumab The risk or severity of adverse effects can be increased when Canakinumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Caplacizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Caplacizumab. Investigational Capromab pendetide The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Capromab pendetide. Approved Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Carlumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Carlumab. Investigational Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental Catumaxomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Catumaxomab. Approved, Investigational, Withdrawn Certolizumab pegol The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Cetuximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cetuximab. Approved Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Cixutumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Cixutumumab. Investigational Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Clazakizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clazakizumab. Investigational Clenoliximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Clenoliximab. Investigational Clobetasol The risk or severity of adverse effects can be increased when Clobetasol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Clobetasone The risk or severity of adverse effects can be increased when Clobetasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Clocortolone The risk or severity of adverse effects can be increased when Clocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Coltuximab ravtansine The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Coltuximab ravtansine. Investigational Conatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Conatumumab. Investigational Concizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Concizumab. Investigational Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Corticosterone The risk or severity of adverse effects can be increased when Corticosterone is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental Corticotropin The risk or severity of adverse effects can be increased when Corticotropin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Vet Approved Cortisone acetate The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational CR002 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with CR002. Investigational Crenezumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Crenezumab. Investigational Crotedumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Crotedumab. Investigational Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Cyclosporine The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Vet Approved Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Dacetuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dacetuzumab. Investigational Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational, Withdrawn Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Dalotuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dalotuzumab. Investigational Daratumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Daratumumab. Approved Dasatinib The risk or severity of adverse effects can be increased when Dasatinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Deflazacort The risk or severity of adverse effects can be increased when Deflazacort is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Demcizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Demcizumab. Investigational Denosumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Denosumab. Approved Deoxyspergualin The risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Depatuxizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Depatuxizumab. Investigational Desonide The risk or severity of adverse effects can be increased when Desonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Vet Approved Dexamethasone The risk or severity of adverse effects can be increased when Dexamethasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Bacillus calmette-guerin substrain connaught live antigen. Vet Approved Diflorasone The risk or severity of adverse effects can be increased when Diflorasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Difluocortolone The risk or severity of adverse effects can be increased when Difluocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Difluprednate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Dimethyl fumarate The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Dinutuximab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Docetaxel The risk or severity of adverse effects can be increased when Docetaxel is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Doxifluridine The risk or severity of adverse effects can be increased when Doxifluridine is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Dulaglutide The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dulaglutide. Approved, Investigational Duligotuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Duligotuzumab. Investigational Dupilumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dupilumab. Approved, Investigational Durvalumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Durvalumab. Approved, Investigational Dusigitumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Dusigitumab. Investigational Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Edrecolomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Edrecolomab. Experimental, Investigational Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Eldelumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Eldelumab. Investigational Elotuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Elotuzumab. Approved Emibetuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Emibetuzumab. Investigational Emicizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Emicizumab. Approved, Investigational Enokizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enokizumab. Investigational Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Epratuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Epratuzumab. Investigational Equilenin The risk or severity of adverse effects can be increased when Equilenin is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental Equilin The risk or severity of adverse effects can be increased when Equilin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Estrone The risk or severity of adverse effects can be increased when Estrone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Etaracizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Etaracizumab. Investigational Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Etrolizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Etrolizumab. Investigational Everolimus The risk or severity of adverse effects can be increased when Everolimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Evolocumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Evolocumab. Approved Farletuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Farletuzumab. Investigational Ficlatuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ficlatuzumab. Investigational Figitumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Figitumumab. Investigational Fingolimod The risk or severity of adverse effects can be increased when Fingolimod is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Firategrast The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Firategrast. Investigational Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fluasterone The risk or severity of adverse effects can be increased when Fluasterone is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Flumethasone The risk or severity of adverse effects can be increased when Flumethasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Fluocinonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Fluocortolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fluprednidene The risk or severity of adverse effects can be increased when Fluprednidene is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Fluprednisolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Flurandrenolide The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fluticasone furoate The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Fontolizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fontolizumab. Investigational Formestane The risk or severity of adverse effects can be increased when Formestane is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Withdrawn Fresolimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fresolimumab. Investigational Fulranumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Fulranumab. Investigational Galiximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Galiximab. Investigational Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ganitumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ganitumab. Investigational Gantenerumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gantenerumab. Investigational Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Gevokizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Gevokizumab. Investigational Glatiramer Acetate The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Glembatumumab vedotin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Glembatumumab vedotin. Investigational Glimepiride The risk or severity of adverse effects can be increased when Glimepiride is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Golimumab The risk or severity of adverse effects can be increased when Golimumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved GS 0573 The risk or severity of adverse effects can be increased when GS 0573 is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Guselkumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Guselkumab. Approved, Investigational Gusperimus The risk or severity of adverse effects can be increased when Gusperimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Halcinonide The risk or severity of adverse effects can be increased when Halcinonide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Withdrawn HE3286 The risk or severity of adverse effects can be increased when HE3286 is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Human C1-esterase inhibitor The risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Human cytomegalovirus immune globulin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Human cytomegalovirus immune globulin. Approved Human Varicella-Zoster Immune Globulin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Human Varicella-Zoster Immune Globulin. Approved Hydrocortisone The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Hypericin The risk or severity of adverse effects can be increased when Hypericin is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Ibalizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ibalizumab. Approved, Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Idarubicin The risk or severity of adverse effects can be increased when Idarubicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Idarucizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Idarucizumab. Approved Idelalisib The risk or severity of adverse effects can be increased when Idelalisib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Ifosfamide The risk or severity of adverse effects can be increased when Ifosfamide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved IGN311 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IGN311. Investigational Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved IMC-1C11 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IMC-1C11. Investigational Imiquimod The risk or severity of adverse effects can be increased when Imiquimod is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Immune Globulin Human The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Immune Globulin Human. Approved, Investigational Inclacumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inclacumab. Investigational Indium In-111 satumomab pendetide The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Indium In-111 satumomab pendetide. Approved, Withdrawn Inebilizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inebilizumab. Investigational Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Inotuzumab ozogamicin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Inotuzumab ozogamicin. Approved, Investigational Intetumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Intetumumab. Investigational IPH 2101 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with IPH 2101. Investigational Ipilimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ipilimumab. Approved Iratumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Iratumumab. Investigational Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Istaroxime The risk or severity of adverse effects can be increased when Istaroxime is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Ixekizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ixekizumab. Approved, Investigational L-Phenylalanine The risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Nutraceutical Labetuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Labetuzumab. Investigational Lampalizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lampalizumab. Investigational Landogrozumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Landogrozumab. Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Lerdelimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lerdelimumab. Investigational Lexatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lexatumumab. Investigational Ligelizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ligelizumab. Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Lorvotuzumab mertansine The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lorvotuzumab mertansine. Investigational Loteprednol The risk or severity of adverse effects can be increased when Loteprednol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Lucatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lucatumumab. Investigational Lumiliximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lumiliximab. Investigational Matuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Matuzumab. Investigational Mavrilimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mavrilimumab. Investigational ME-609 The risk or severity of adverse effects can be increased when ME-609 is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Medrysone The risk or severity of adverse effects can be increased when Medrysone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Melengestrol The risk or severity of adverse effects can be increased when Melengestrol is combined with Bacillus calmette-guerin substrain connaught live antigen. Vet Approved Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Milatuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Milatuzumab. Investigational Mirvetuximab Soravtansine The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mirvetuximab Soravtansine. Investigational Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Mitoxantrone The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Mogamulizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Mogamulizumab. Investigational Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Motavizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Motavizumab. Investigational Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved MYO-029 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with MYO-029. Investigational Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Naptumomab Estafenatox The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Naptumomab Estafenatox. Investigational Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when NCX 1022 is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Nebacumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nebacumab. Experimental Necitumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Necitumumab. Approved, Investigational Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Nilotinib The risk or severity of adverse effects can be increased when Nilotinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Nimotuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nimotuzumab. Investigational Nivolumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nivolumab. Approved Obiltoxaximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Obiltoxaximab. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ocrelizumab The therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ofatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ofatumumab. Approved Olaratumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Olaratumab. Approved, Investigational Oleoyl-estrone The risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Olokizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Olokizumab. Investigational Omalizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Omalizumab. Approved, Investigational Onartuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Onartuzumab. Investigational Oregovomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Oregovomab. Investigational Otelixizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Otelixizumab. Investigational Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Ozanezumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ozanezumab. Investigational Paclitaxel The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Palbociclib The risk or severity of adverse effects can be increased when Palbociclib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Palivizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Palivizumab. Approved, Investigational Panitumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Panitumumab. Approved, Investigational Panobinostat The risk or severity of adverse effects can be increased when Panobinostat is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Paquinimod The risk or severity of adverse effects can be increased when Paquinimod is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Paramethasone The risk or severity of adverse effects can be increased when Paramethasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Patritumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Patritumab. Investigational Pazopanib The risk or severity of adverse effects can be increased when Pazopanib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Pembrolizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pembrolizumab. Approved Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Pertuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pertuzumab. Approved Pexelizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Pexelizumab. Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Pirarubicin The risk or severity of adverse effects can be increased when Pirarubicin is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Polatuzumab Vedotin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Polatuzumab Vedotin. Investigational Pomalidomide The risk or severity of adverse effects can be increased when Pomalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Prasterone The risk or severity of adverse effects can be increased when Prasterone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Prednicarbate is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Pregnenolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Experimental, Investigational PRO 140 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with PRO 140. Investigational PRO-542 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with PRO-542. Investigational Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational R1507 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with R1507. Investigational Racotumomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Racotumomab. Investigational Ramucirumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ramucirumab. Approved, Investigational Ranibizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Ranibizumab. Approved Raxibacumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Raxibacumab. Approved Reslizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Reslizumab. Approved, Investigational RI 624 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with RI 624. Investigational RIGScan CR49 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with RIGScan CR49. Investigational Rilonacept The risk or severity of adverse effects can be increased when Rilonacept is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Rilotumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rilotumumab. Investigational Rimexolone The risk or severity of adverse effects can be increased when Rimexolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Robatumumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Robatumumab. Investigational Romosozumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Romosozumab. Investigational Rontalizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Rontalizumab. Investigational Ruxolitinib The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Sacituzumab govitecan The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sacituzumab govitecan. Investigational Sarilumab The risk or severity of infection can be increased when Sarilumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Secukinumab The risk or severity of adverse effects can be increased when Secukinumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Seocalcitol The risk or severity of adverse effects can be increased when Seocalcitol is combined with Bacillus calmette-guerin substrain connaught live antigen. Experimental, Investigational Seribantumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Seribantumab. Investigational Sibrotuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sibrotuzumab. Investigational Siltuximab The risk or severity of adverse effects can be increased when Siltuximab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Siplizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Siplizumab. Investigational Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Sirukumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sirukumab. Investigational Solanezumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Solanezumab. Investigational Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Sulesomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Sulesomab. Approved Sunitinib The risk or severity of adverse effects can be increased when Sunitinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational SYM001 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with SYM001. Investigational Tabalumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tabalumab. Investigational Tacrolimus The risk or severity of adverse effects can be increased when Tacrolimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Tanezumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tanezumab. Investigational Tarextumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tarextumab. Investigational TB-402 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TB-402. Investigational Technetium Tc-99m arcitumomab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Technetium Tc-99m arcitumomab. Approved, Investigational Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Temsirolimus The risk or severity of adverse effects can be increased when Temsirolimus is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Teplizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Teplizumab. Investigational Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Bacillus calmette-guerin substrain connaught live antigen. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Tetanus Immune Globulin The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tetanus Immune Globulin. Approved Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Withdrawn Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Tildrakizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tildrakizumab. Approved Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Tixocortol The risk or severity of adverse effects can be increased when Tixocortol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Withdrawn TNX-901 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TNX-901. Investigational Tocilizumab The risk or severity of adverse effects can be increased when Tocilizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Tofacitinib The risk or severity of adverse effects can be increased when Tofacitinib is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Tovetumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tovetumab. Investigational Trabectedin The risk or severity of adverse effects can be increased when Trabectedin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Tralokinumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tralokinumab. Investigational Trastuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Trastuzumab. Approved, Investigational Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational TRC105 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with TRC105. Investigational Tremelimumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Tremelimumab. Investigational Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational, Nutraceutical Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Trofosfamide The risk or severity of adverse effects can be increased when Trofosfamide is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Ulobetasol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Vedolizumab The risk or severity of adverse effects can be increased when Vedolizumab is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Veltuzumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Veltuzumab. Investigational Vilanterol The risk or severity of adverse effects can be increased when Vilanterol is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Visilizumab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Visilizumab. Investigational Voclosporin The risk or severity of adverse effects can be increased when Voclosporin is combined with Bacillus calmette-guerin substrain connaught live antigen. Investigational Volociximab The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Volociximab. Investigational XmAb 2513 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with XmAb 2513. Investigational XTL-001 The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with XTL-001. Investigational - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347910910
- AHFS Codes
- 80:12.00 — Vaccines
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Recruiting Treatment Bladder Cancers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Injection, powder, lyophilized, for solution Intravesical 81 mg/3mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on December 01, 2015 13:04 / Updated on April 23, 2018 23:14